Northwest Biotherapeutics (NWBO) Total Liabilities (2010 - 2026)

Northwest Biotherapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $118.1 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 5.13% year-over-year to $118.1 million in Q1 2026; TTM through Mar 2026 was $118.1 million, a 5.13% increase from a year earlier, with the FY2025 full-year figure at $128.9 million, up 21.9% from the prior year.
• Total Liabilities fell to $118.1 million in Q1 2026 per NWBO's latest filing, from $128.9 million in the prior quarter.
• Across five years, Total Liabilities topped out at $151.2 million in Q1 2022 and bottomed at $64.1 million in Q2 2023.
• The 5-year median for Total Liabilities is $112.3 million (2025), against an average of $104.4 million.
• Across the five-year window, Total Liabilities slumped 68.52% in 2022 and jumped 41.09% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $136.4 million in 2022, then sank by 45.06% to $74.9 million in 2023, then soared by 41.09% to $105.7 million in 2024, then increased by 21.9% to $128.9 million in 2025, then dropped by 8.34% to $118.1 million in 2026.
• Per Business Quant, the three latest NWBO Total Liabilities figures stand at $118.1 million (Q1 2026), $128.9 million (Q4 2025), and $125.9 million (Q3 2025).